This company has been marked as potentially delisted and may not be actively trading. Digirad (DRAD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock DRAD vs. NRXS, VRAYQ, VIVE, ELMD, QTI, MODD, TELO, GBIO, UG, and XFORShould you be buying Digirad stock or one of its competitors? The main competitors of Digirad include NeurAxis (NRXS), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), QT Imaging (QTI), Modular Medical (MODD), Telomir Pharmaceuticals (TELO), Generation Bio (GBIO), United-Guardian (UG), and X4 Pharmaceuticals (XFOR). These companies are all part of the "medical" sector. Digirad vs. Its Competitors NeurAxis ViewRay Viveve Medical Electromed QT Imaging Modular Medical Telomir Pharmaceuticals Generation Bio United-Guardian X4 Pharmaceuticals NeurAxis (NASDAQ:NRXS) and Digirad (NASDAQ:DRAD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Which has more volatility and risk, NRXS or DRAD? NeurAxis has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500. Comparatively, Digirad has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Does the media prefer NRXS or DRAD? In the previous week, NeurAxis had 2 more articles in the media than Digirad. MarketBeat recorded 2 mentions for NeurAxis and 0 mentions for Digirad. Digirad's average media sentiment score of 0.00 beat NeurAxis' score of -1.00 indicating that Digirad is being referred to more favorably in the news media. Company Overall Sentiment NeurAxis Negative Digirad Neutral Do analysts rate NRXS or DRAD? NeurAxis currently has a consensus target price of $7.00, suggesting a potential upside of 199.15%. Given NeurAxis' stronger consensus rating and higher possible upside, research analysts plainly believe NeurAxis is more favorable than Digirad.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Digirad 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, NRXS or DRAD? Digirad has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Digirad, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurAxis$3.22M7.18-$14.63M-$0.99-2.36Digirad$114.18M0.00-$4.63M-$0.35N/A Is NRXS or DRAD more profitable? Digirad has a net margin of -5.32% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Digirad's return on equity.Company Net Margins Return on Equity Return on Assets NeurAxis-492.76% N/A -641.25% Digirad -5.32%-3.75%-0.85% Do institutionals & insiders believe in NRXS or DRAD? 11.8% of NeurAxis shares are held by institutional investors. Comparatively, 11.4% of Digirad shares are held by institutional investors. 26.4% of NeurAxis shares are held by company insiders. Comparatively, 12.5% of Digirad shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryNeurAxis beats Digirad on 8 of the 15 factors compared between the two stocks. Get Digirad News Delivered to You Automatically Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRAD vs. The Competition Export to ExcelMetricDigiradElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.14M$44.72M$5.80B$10.16BDividend Yield83.65%N/A5.72%4.60%P/E Ratio-0.684.1375.1326.39Price / SalesN/A221.20508.32174.86Price / Cash0.6941.3625.8129.91Price / BookN/A2.5313.716.28Net Income-$4.63M-$2.66M$3.29B$270.38M Digirad Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRADDigiradN/AN/AN/A-48.3%$10.14M$114.18M-0.68618High Trading VolumeNRXSNeurAxis2.0673 of 5 stars$2.45+1.2%$7.00+185.7%-21.2%$23.89M$3.22M-1.3319News CoverageNegative NewsShort Interest ↑VRAYQViewRayN/AN/AN/AN/A$18K$102.21M0.00300Gap DownVIVEViveve MedicalN/AN/AN/AN/A$1K$6.83M0.0070ELMDElectromed3.998 of 5 stars$26.61+6.6%$36.25+36.2%+35.5%$222.17M$64M35.48160News CoverageQTIQT ImagingN/A$2.52+1.6%N/A+388.0%$68.38M$4.00M0.00N/AMODDModular Medical1.2488 of 5 stars$0.71-1.5%N/A-67.9%$39.80MN/A-1.3920News CoverageGap UpTELOTelomir Pharmaceuticals1.9825 of 5 stars$1.36+10.6%$15.00+1,002.9%-78.1%$39.71MN/A-2.521GBIOGeneration Bio4.039 of 5 stars$6.15+5.5%$10.67+73.4%-78.5%$39.27M$21.23M-0.57150Short Interest ↓UGUnited-Guardian2.386 of 5 stars$8.50+0.5%N/A-44.8%$38.82M$10.86M15.1720Positive NewsXFORX4 Pharmaceuticals4.6387 of 5 stars$3.28-3.2%$34.17+941.7%-86.0%$38.67M$32.77M-0.2280Short Interest ↓ Related Companies and Tools Related Companies NeurAxis Competitors ViewRay Competitors Viveve Medical Competitors Electromed Competitors QT Imaging Competitors Modular Medical Competitors Telomir Pharmaceuticals Competitors Generation Bio Competitors United-Guardian Competitors X4 Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRAD) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Digirad Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Digirad With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRAD Stock Alerts